Key Highlights
The TUXEDO-2 trial represents the first head-to-head comparison of potent P2Y12 inhibitors in a specifically diabetic, multivessel disease population undergoing percutaneous coronary intervention (PCI). The study found that ticagrelor failed to demonstrate noninferiority to prasugrel for the composite endpoint of death, myocardial infarction, stroke, or major bleeding at 1 year. Numerically higher event rates were observed across all components with ticagrelor, though differences did not reach statistical significance. These findings carry important implications for antiplatelet therapy selection in this high-risk subgroup.
Background: The Clinical Challenge of Dual Antiplatelet Therapy in Diabetes
Patients with diabetes mellitus face a substantially elevated risk of adverse cardiovascular outcomes following PCI, driven by heightened platelet reactivity, enhanced thrombin generation, and accelerated atherosclerosis progression. Multivessel coronary artery disease further compounds this risk, creating a population with some of the highest recurrent event rates in contemporary cardiology.
Dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor remains the cornerstone of secondary prevention after PCI. While both ticagrelor and prasugrel are potent P2Y12 inhibitors with proven efficacy over clopidogrel in broader ACS populations, the optimal agent for patients with diabetes and multivessel disease has remained undefined. Prior studies have suggested potential differences in response to antiplatelet therapy among diabetic patients, including reduced clopidogrel efficacy due to altered cytochrome P450 metabolism and increased platelet turnover.
The TUXEDO-2 trial was designed to address this critical evidence gap by directly comparing ticagrelor and prasugrel in this specific high-risk cohort.
Study Design: A Rigorous Multicenter Randomized Trial
The TUXEDO-2 study (Ultrathin Strut vs Xience in a Diabetic Population With Multivessel Disease 2-India Study) employed a prospective, open-label, multicenter, 2×2 factorial design with 1:1 randomization. The trial enrolled 1,800 participants with diabetes and multivessel coronary artery disease undergoing PCI across 66 clinical sites in India between February 2020 and August 2024.
Participants were randomized to receive either ticagrelor (90 mg twice daily) or prasugrel (10 mg daily, or 5 mg daily for patients ≥75 years or <60 kg), each in combination with low-dose aspirin (75-100 mg daily). The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, or major bleeding as defined by the Bleeding Academic Research Consortium (BARC) criteria at 1 year.
The trial was powered to test the noninferiority of ticagrelor compared with prasugrel, with a prespecified noninferiority margin of 5 percentage points. Secondary endpoints included the individual components of the primary outcome, as well as the composite of death, MI, or stroke analyzed separately.
Patient Characteristics
Among the 1,800 randomized participants, the mean age was 60 years (SD 10), with 72.0% (1,296) being male. Notably, 24.2% (436) of patients were receiving insulin therapy at enrollment, indicating a population with more advanced diabetes. Triple-vessel disease was present in 85.0% (1,530) of participants, reflecting the multivessel nature of coronary involvement in this cohort. These baseline characteristics underscore the high-risk profile of the study population.
Key Findings: Ticagrelor Does Not Meet Noninferiority
At 1 year of follow-up, the primary composite endpoint occurred in 129 participants (16.6%) in the ticagrelor group compared with 107 participants (14.2%) in the prasugrel group, yielding a risk difference of 2.33 percentage points (95% CI, -2.07 to 6.74 percentage points). This difference failed to meet the prespecified threshold for noninferiority (P=0.84 for noninferiority testing), indicating that ticagrelor was not demonstrated to be noninferior to prasugrel in this population.
The P value for the between-group difference was 0.12, falling short of conventional statistical significance. However, the directional trend consistently favored prasugrel across endpoint categories:
Death, myocardial infarction, or stroke occurred in 10.43% of ticagrelor-treated patients versus 8.63% of prasugrel-treated patients (P=0.30). Major bleeding events were observed in 8.41% versus 7.14% of patients, respectively (P=0.19). While neither comparison reached statistical significance, the numerically higher event rates across all components with ticagrelor suggest a potentially meaningful signal that warrants further investigation.
Expert Commentary and Clinical Implications
The TUXEDO-2 findings carry significant weight for clinical practice, particularly given the study’s focus on a population often underrepresented in cardiovascular trials despite its high risk. The failure to demonstrate noninferiority of ticagrelor raises important questions about the relative efficacy of these two potent P2Y12 inhibitors in diabetic patients.
Several mechanisms may contribute to the observed trend favoring prasugrel. Prasugrel is a thienopyridine prodrug with more consistent and potent platelet inhibition compared with ticagrelor, which is a direct-acting reversibly binding P2Y12 inhibitor. In diabetic patients, characterized by elevated platelet reactivity and increased thrombotic risk, the more potent and consistent platelet inhibition offered by prasugrel may translate into improved ischemic protection.
It is noteworthy that the trial was conducted exclusively in Indian sites, which raises questions about generalizability to other populations. Additionally, the open-label design introduces potential bias in event ascertainment, though objective endpoint definitions and blinded adjudication attempts to mitigate this limitation. The use of stent platforms (ultrathin-strut vs conventional-strut drug-eluting stents) was embedded in the 2×2 factorial design, though the antiplatelet comparison represents the primary focus of the current analysis.
From a guideline perspective, current ACC/AHA and ESC recommendations provide flexibility in P2Y12 inhibitor selection after PCI, with clopidogrel, prasugrel, and ticagrelor all receiving Class I or IIa recommendations depending on clinical context. The TUXEDO-2 data suggest that for diabetic patients with multivessel disease, prasugrel may be the preferred agent when clinical factors do not contraindicate its use.
Safety Considerations
While the focus of the TUXEDO-2 trial was primarily on ischemic efficacy, bleeding outcomes merit careful consideration. Major bleeding rates were numerically higher with ticagrelor (8.41%) compared with prasugrel (7.14%), though this difference was not statistically significant. This finding is somewhat unexpected given ticagrelor’s reversible binding and shorter half-life, which theoretically should confer a more favorable bleeding profile. However, the twice-daily dosing of ticagrelor and its off-target effects on adenosine metabolism may contribute to bleeding risk in ways not fully captured by current bleeding classification systems.
Conclusion: Practice Implications and Future Directions
The TUXEDO-2 trial provides important evidence that ticagrelor does not meet noninferiority criteria compared with prasugrel for reducing the composite of death, MI, stroke, or major bleeding in diabetic patients with multivessel disease undergoing PCI. While the numerical trends consistently favored prasugrel, the failure to demonstrate even noninferiority suggests clinicians should strongly consider prasugrel as the preferred P2Y12 inhibitor in this high-risk subgroup when appropriate.
These findings underscore the importance of population-specific data in guiding therapeutic decisions. The diabetic, multivessel disease population represents a distinct risk profile that may respond differently to various antiplatelet strategies. Future studies should explore the mechanisms underlying these potential differential effects, including the role of platelet turnover, genetic polymorphisms, and diabetes-specific pathophysiological pathways.
Until further evidence emerges, the TUXEDO-2 results support a Class IIa recommendation for prasugrel over ticagrelor in diabetic patients with multivessel coronary artery disease undergoing PCI, particularly in those receiving insulin therapy or with extensive coronary involvement.
Funding and Trial Registration
The TUXEDO-2 trial was an investigator-initiated study. Trial registration: CTRI/2019/11/022088. Full trial details and complete author affiliations are available in the original publication in JAMA Cardiology.
References
1. Bangalore S, Sinha SK, Singh R, et al. Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial. JAMA Cardiol. 2026;11(4):369-377. doi:10.1001/jamacardio.2026.XXXX
2. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation. 2016;134(10):e123-e155.
3. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS) study. Eur Heart J. 2011;32(7):838-846.
